TOP
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Sequana Medical NV
Transparency Notifications from Shareholders
April 03, 2024
From
Sequana Medical NV
Via
GlobeNewswire
Strong data from DSR® proof-of-concept studies in heart failure published in European Journal of Heart Failure
April 03, 2024
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces 2023 Full Year Results and 2024 Outlook
March 28, 2024
From
Sequana Medical NV
Via
GlobeNewswire
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
March 26, 2024
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort confirming dramatic improvement in diuretic response and virtual elimination of loop diuretics following DSR® therapy
March 25, 2024
From
Sequana Medical NV
Via
GlobeNewswire
Strong data from DSR® proof-of-concept studies in heart failure accepted for late-breaking presentation at THT 2024
February 28, 2024
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces FDA acceptance for substantive review of the Premarket Approval application for alfapump® in recurrent or refractory ascites due to liver cirrhosis
January 29, 2024
From
Sequana Medical NV
Via
GlobeNewswire
Transparency Notifications from Shareholders
January 24, 2024
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces DSMB approval to start randomized MOJAVE cohort – US Phase 1/2a study of DSR® 2.0 for treatment of heart failure
January 23, 2024
From
Sequana Medical NV
Via
GlobeNewswire
Transparency Notifications from Shareholders
January 15, 2024
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical granted US CPT® III reimbursement codes for alfapump® system
January 03, 2024
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical submits Premarket Approval application to US FDA for alfapump® in recurrent or refractory ascites due to liver cirrhosis
December 28, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces positive data from non-randomized cohort in US Phase 1/2a MOJAVE study of DSR® 2.0 for treatment of heart failure
November 29, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces results of Extraordinary General Meeting of Shareholders
November 10, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces additional alfapump data supporting strong and durable clinical profile; PMA on track for year-end submission
October 19, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces initial positive data from MOJAVE, a US Phase 1/2a study of DSR® 2.0 for treatment of heart failure through breaking vicious cycle of cardiorenal syndrome
October 18, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces H1 2023 results and provides business update
September 14, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical Notice of 2023 Half-year Results and Business Update
September 06, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure
July 10, 2023
From
Sequana Medical NV
Via
GlobeNewswire
1,000th alfapump® implant completed
July 06, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces results of Special General Meeting of Shareholders
June 26, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces additional data on safety, quality of life and survival from North American pivotal alfapump® study (POSEIDON)
June 21, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Additional data from North American pivotal alfapump® study (POSEIDON) will be presented at EASL Congress 2023
June 19, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical wins Best Technology Award for alfapump® at European Mediscience Awards
June 16, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces Special General Meeting of Shareholders on 26 June 2023
May 26, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces results of Annual General Meeting of Shareholders
May 25, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Transparency Notifications from Shareholders
May 15, 2023
From
Sequana Medical NV
Via
GlobeNewswire
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
May 10, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces FDA clearance of IND application for DSR® 2.0 for treatment of congestive heart failure
May 02, 2023
From
Sequana Medical NV
Via
GlobeNewswire
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
April 27, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
BOTTOM